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Recent clinical advances underscored that elimination of
tumor-induced immunosuppression is prerequisite for
successful therapy of advanced human cancers. The
myeloid-derived suppressor cells (MDSCs) are one of
the major populations limiting T cell-mediated antitu-
mor immune responses in late-stage solid tumors, such
as castration-resistant prostate cancers (CRPCs). Target-
ing MDSCs proved challenging due to their heterogene-
ity and phenotypic similarities with other myeloid cell
lineages. Here, we identify a population of granulocytic
MDSCs, which accumulate in patients’ blood during
progression of prostate cancer from localized to meta-
static disease. The CRPC-associated MDSCs potently
inhibit proliferation, IFN-g and Granzyme-B production
in autologous CD8+ T cells. Importantly, the MDSCs in
blood and in lymph nodes of CRPC patients show high
levels of activated STAT3 transcription factor, which is a
crucial immune checkpoint regulator. We previously gen-
erated an original method to silence genes specifically in
TLR9+ myeloid cells using CpG-siRNA conjugates [1,2].
Now, we demonstrate that the CpG-STAT3siRNA is also
effectively internalized by human MDSCs and induces
STAT3 silencing without the need for transfection
reagents. Our further studies demonstrated that two-
pronged TLR9-activation/STAT3-blocking by CpG-
STAT3siRNA inhibits immunosuppressive effects of
CRPC-MDSCs on CD8+ T cells, while both TLR9 trigger-
ing or STAT3 inhibition alone have only minimal effects.
The reversal of MDSC immunosuppression by CpG-
STAT3 siRNA results from reduced expression and enzy-
matic activity of Arginase I, a downstream STAT3 target
gene. Overall, our study demonstrates the feasibility of
overcoming immunosuppression in CRPC patients using
CpG-STAT3siRNA strategy to alleviate effects of MDSCs.
We anticipate that our strategy to reverse MDSC-
mediated immunosuppression without depleting myeloid
cell populations will generate safer and more effective
immunotherapy for late-stage, metastatic prostate cancers
and potentially other solid tumors.
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